Advertisement

Preclinical Imaging in BSL-3 and BSL-4 Environments: Imaging Pathophysiology of Highly Pathogenic Infectious Diseases

  • Lauren Keith
  • Svetlana Chefer
  • Laura Bollinger
  • Jeffrey Solomon
  • Srikanth Yellayi
  • Jurgen Seidel
  • David Thomasson
  • Peter Jahrling
Chapter
Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 8)

Abstract

Structural and functional imaging are emerging as powerful tools for studying highly pathogenic infectious disease processes. Nuclear imaging modalities and sophisticated radiolabeled probes can be used to track physiological or biochemical processes associated with viral infection. Magnetic resonance imaging can provide anatomical images with exquisite soft tissue contrast, while magnetic resonance spectroscopy can measure the relative amounts of certain metabolites in a given tissue. However, conducting medical imaging studies in a high-containment laboratory requires advanced applications and modification not only of image acquisition and analysis processes but also of the imaging equipment. Processes such as ex vivo labeling of cells are hampered by the personal protective equipment required for the safety of laboratory personnel. Modification of medical imaging equipment can prevent contamination of the equipment. Regardless of the challenges involved, medical imaging could provide valuable information to researchers developing therapeutics against highly pathogenic infectious diseases.

Keywords

West Nile Virus Personal Protective Equipment Imaging Equipment Service Engineer Containment Strategy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors thank Fabian de Kok-Mercado for his contribution to this work. The content of this chapter does not necessarily reflect the views or policies of the US Department of Health and Human Services or of the institutions and companies affiliated with the authors. This work was supported by the Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), and Battelle Memorial Institute’s prime contract with NIAID (HHSN272200200016I).

References

  1. Bading JR, Shields AF (2008) Imaging of cell proliferation: status and prospects. J Nucl Med 49(Suppl 2):64S–80SPubMedCrossRefGoogle Scholar
  2. Beckmann N et al (2003) Macrophage infiltration into the rat knee detected by MRI in a model of antigen-induced arthritis. Magn Reson Med 49(6):1047–1055PubMedCrossRefGoogle Scholar
  3. Bellani G et al (2010) Imaging of lung inflammation during severe influenza A: H1N1. Intensive Care Med 36(4):717–718PubMedCrossRefGoogle Scholar
  4. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95CrossRefGoogle Scholar
  5. Blaimer M et al (2004) SMASH, SENSE, PILS, GRAPPA: how to choose the optimal method. Top Magn Reson Imaging 15(4):223–236PubMedCrossRefGoogle Scholar
  6. Bray M et al (2010) Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes. Antiviral Res 88(2):129–142PubMedCrossRefGoogle Scholar
  7. Brunetti A et al (1989) Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3′-azido-2′,3′-dideoxythymidine (AZT, zidovudine): a PET-FDG study. J Nucl Med 30(5):581–590PubMedGoogle Scholar
  8. Brust D et al (2006) Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS 20(7):985–993PubMedCrossRefGoogle Scholar
  9. Bulte JW (2009) In vivo MRI cell tracking: clinical studies. Am J Roentgenol 193(2):314–325CrossRefGoogle Scholar
  10. Burton JM et al (2004) Neurological manifestations of West Nile virus infection. Can J Neurol Sci 31(2):185–193PubMedGoogle Scholar
  11. Buscombe JR, Oyen WJ, Corstens FH (1995) Use of polyclonal IgG in HIV infection and AIDS. Q J Nucl Med 39(3):212–220PubMedGoogle Scholar
  12. Chaljub G et al (2001) Projectile cylinder accidents resulting from the presence of ferromagnetic nitrous oxide or oxygen tanks in the MR suite. Am J Roentgenol 177(1):27–30CrossRefGoogle Scholar
  13. Cherry SR, Sorenson JA, Phelps ME (2003) The gamma camera: performance characteristics. In: Physics in nuclear medicine. Saunders, Philadephia, PAGoogle Scholar
  14. Cyran CC et al (2012) Permeability to macromolecular contrast media quantified by dynamic MRI correlates with tumor tissue assays of vascular endothelial growth factor (VEGF). Eur J Radiol 81(5):891–896PubMedCrossRefGoogle Scholar
  15. Dannels WR et al (2008) Integrated system of MRI RF loop coils plus spacing fixtures with biocontainment tubes. WIPO Patent Application. PCT/US2008 073512, filed June 19, 2008Google Scholar
  16. de Kok-Mercado F, Kutlak F, Jahrling PB (2011) The NIAID integrated research facility at Fort Detrick. Appl Biosafety 16(2):58–66Google Scholar
  17. Di Mascio M et al (2009) Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography. Antimicrob Agents Chemother 53(10):4086–4095PubMedCrossRefGoogle Scholar
  18. Dotti G et al (2009) Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU. Mol Imaging 8(4):230–237PubMedGoogle Scholar
  19. Dyall J et al (2011) Evaluation of monkeypox disease progression by molecular imaging. J Infect Dis 204(12):1902–1911PubMedCrossRefGoogle Scholar
  20. Dyall J et al (2012) Assessment of longitudinal changes in 18FDG uptake in bone marrow and lymph node and in lymph node volume in nonhuman primate model of monkeypox infection. World Molecular Imaging Congress Dublin, Ireland, Sep 5–8 2012Google Scholar
  21. Ferro-Flores G, Ocampo-Garcia BE, Melendez-Alafort L (2012) Development of specific radiopharmaceuticals for infection imaging by targeting infectious micro-organisms. Curr Pharm Des 18(8):1098–1106PubMedCrossRefGoogle Scholar
  22. Floris S et al (2004) Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 127(Pt 3):616–627PubMedGoogle Scholar
  23. Frank JA et al (2003) Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology 228(2):480–487PubMedCrossRefGoogle Scholar
  24. Gambhir SS et al (2000) Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2(1–2):118–138PubMedCrossRefGoogle Scholar
  25. Garg M et al (2008) Radiolabeling, pharmacoscintigraphic evaluation and antiretroviral efficacy of stavudine loaded 99mTc labeled galactosylated liposomes. Eur J Pharm Sci 33(3):271–281PubMedCrossRefGoogle Scholar
  26. Haacke EM et al (2004) Susceptibility weighted imaging (SWI). Magn Reson Med 52(3): 612–618PubMedCrossRefGoogle Scholar
  27. Hamed IA et al (1979) Pulmonary cytomegalovirus infection: detection by Gallium 67 imaging in the transplant patient. Arch Intern Med 139(3):286–288PubMedCrossRefGoogle Scholar
  28. Hayes EB, Gubler DJ (2006) West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med 57:181–194PubMedCrossRefGoogle Scholar
  29. Hoehn M et al (2007) Cell tracking using magnetic resonance imaging. J Physiol 584(Pt 1):25–30PubMedCrossRefGoogle Scholar
  30. Jain NK et al (2010) Biosafety level (BSL)-3 life support cell for studying live animals. Patent Application. PCT/US20100313821, filed June 16, 2010Google Scholar
  31. Jeha LE et al (2003) West Nile virus infection: a new acute paralytic illness. Neurology 61(1):55–59PubMedCrossRefGoogle Scholar
  32. Jubeli E et al (2012) E-selectin as a target for drug delivery and molecular imaging. J Control Release 158(2):194–206PubMedCrossRefGoogle Scholar
  33. Kleinschnitz C et al (2003) In vivo monitoring of macrophage infiltration in experimental ischemic brain lesions by magnetic resonance imaging. J Cereb Blood Flow Metab 23(11):1356–1361PubMedCrossRefGoogle Scholar
  34. Kumar V (2005) Radiolabeled white blood cells and direct targeting of micro-organisms for infection imaging. Q J Nucl Med 49(4):325–338Google Scholar
  35. Kumar S et al (1997) MRI in Japanese encephalitis. Neuroradiology 39(3):180–184PubMedCrossRefGoogle Scholar
  36. Kumar M et al (2010) Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res 70(19):7553–7561PubMedCrossRefGoogle Scholar
  37. Leyson C et al (2012) Performance comparison of ultra-ultra high resolution collimators to low-energy high resolution collimators. J Nucl Med 53(suppl 1):2409Google Scholar
  38. Liu N et al (2007) Radiolabeling small RNA with technetium-99m for visualizing cellular delivery and mouse biodistribution. Nucl Med Biol 34(4):399–404PubMedCrossRefGoogle Scholar
  39. Liu T et al (2012) Cerebral microbleeds: burden assessment by using quantitative susceptibility mapping. Radiology 262(1):269–278PubMedCrossRefGoogle Scholar
  40. Lobel U et al (2010) Three-dimensional susceptibility-weighted imaging and two-dimensional T2*-weighted gradient-echo imaging of intratumoral hemorrhages in pediatric diffuse intrinsic pontine glioma. Neuroradiology 52(12):1167–1177PubMedCrossRefGoogle Scholar
  41. Luker GD, Sharma V, Piwnica-Worms D (2003) Visualizing protein-protein interactions in living animals. Methods 29(1):110–122PubMedCrossRefGoogle Scholar
  42. Modo M, Hoehn M, Bulte JW (2005) Cellular MR imaging. Mol Imaging 4(3):143–164PubMedGoogle Scholar
  43. Nahrendorf M et al (2006) Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114(14):1504–1511PubMedCrossRefGoogle Scholar
  44. O’Connor JP et al (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96(2):189–195PubMedCrossRefGoogle Scholar
  45. O’Connor JP et al (2008) Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol 9(8):766–776PubMedCrossRefGoogle Scholar
  46. Padhani AR et al (2000) Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 55(2):99–109PubMedCrossRefGoogle Scholar
  47. Penheiter AR, Russell SJ, Carlson SK (2012) The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther 12(1):33–47PubMedCrossRefGoogle Scholar
  48. Pien HH et al (2005) Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov Today 10(4):259–266PubMedCrossRefGoogle Scholar
  49. Ratai EM et al (2010) Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS. PLoS One 5(5):e10523PubMedCrossRefGoogle Scholar
  50. Reinders Folmer SC et al (1986) Gallium-67 lung scintigraphy in patients with acquired immune deficiency syndrome (AIDS). Eur J Respir Dis 68(5):313–318PubMedGoogle Scholar
  51. Richter WS (2006) Imaging biomarkers as surrogate endpoints for drug development. Eur J Nucl Med Mol Imaging 33(Suppl 1):6–10PubMedCrossRefGoogle Scholar
  52. Rojas JJ, Thorne SH (2012) Theranostic potential of oncolytic vaccinia virus. Theranostics 2(4):363–373PubMedCrossRefGoogle Scholar
  53. Rubin RH, Fischman AJ (1994) The use of radiolabeled nonspecific immunoglobulin in the detection of focal inflammation. Semin Nucl Med 24(2):169–179PubMedCrossRefGoogle Scholar
  54. Rudin M, Weissleder R (2003) Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2(2):123–131PubMedCrossRefGoogle Scholar
  55. Schellingerhout D et al (1998) Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther 9(11):1543–1549PubMedCrossRefGoogle Scholar
  56. Sejvar JJ et al (2003) Neurologic manifestations and outcome of West Nile virus infection. JAMA 290(4):511–515PubMedCrossRefGoogle Scholar
  57. Sharma V, Luker GD, Piwnica-Worms D (2002) Molecular imaging of gene expression and protein function in vivo with PET and SPECT. J Magn Reson Imaging 16(4):336–351PubMedCrossRefGoogle Scholar
  58. Shoji H et al (1994) Magnetic resonance imaging findings in Japanese encephalitis. White matter lesions. J Neuroimaging 4(4):206–211PubMedGoogle Scholar
  59. Shu CJ et al (2010) Novel PET probes specific for deoxycytidine kinase. J Nucl Med 51(7):1092–1098PubMedCrossRefGoogle Scholar
  60. Smith JJ, Sorensen AG, Thrall JH (2003) Biomarkers in imaging: realizing radiology’s future. Radiology 227(3):633–638PubMedCrossRefGoogle Scholar
  61. Stoll G et al (2004) In vivo monitoring of macrophage infiltration in experimental autoimmune neuritis by magnetic resonance imaging. J Neuroimmunol 149(1–2):142–146PubMedCrossRefGoogle Scholar
  62. Umenai T et al (1985) Japanese encephalitis: current worldwide status. Bull World Health Organ 63(4):625–631PubMedGoogle Scholar
  63. US Department of Agriculture (2005) Agriculture bioterrorism protection act of 2002; possession, use and transfer of select agents and toxins, final rule. Fed Regist 70(52):13294Google Scholar
  64. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health (2009) In: Chosewood LC, Wilson DE (eds) Biosafety in microbiological and biomedical laboratories, 5th edn. US Government Printing Office: Washington, DC. http://www.cdc.gov/biosafety/publications/bmbl5/. Accessed 5 Dec 2012
  65. US Food and Drug Administration (2002) New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Fed Regist 67(105):37988–37998Google Scholar
  66. Valadon P et al (2006) Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc Natl Acad Sci USA 103(2):407–412PubMedCrossRefGoogle Scholar
  67. Venneti S et al (2004) PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS. J Clin Invest 113(7):981–989PubMedGoogle Scholar
  68. Viglianti BL et al (2004) In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med 51(6):1153–1162PubMedCrossRefGoogle Scholar
  69. Wanahita A et al (2007) Diagnostic sensitivity and specificity of the radionuclide (indium)-labeled leukocyte scan. J Infect 55(3):214–219PubMedCrossRefGoogle Scholar
  70. Wang YX, Deng M (2010) Medical imaging in new drug clinical development. J Thorac Dis 2(4):245–252PubMedGoogle Scholar
  71. Willmann JK et al (2008) Molecular imaging in drug development. Nat Rev Drug Discov 7(7):591–607PubMedCrossRefGoogle Scholar
  72. Yarchoan R et al (1987) Response of human-immunodeficiency-virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet 1(8525):132–135PubMedCrossRefGoogle Scholar
  73. Zimmer C et al (2004) Near-miss accident during magnetic resonance imaging by a “flying sevoflurane vaporizer” due to ferromagnetism undetectable by handheld magnet. Anesthesiology 100(5):1329–1330PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2014

Authors and Affiliations

  • Lauren Keith
    • 1
  • Svetlana Chefer
    • 1
  • Laura Bollinger
    • 1
  • Jeffrey Solomon
    • 1
  • Srikanth Yellayi
    • 1
  • Jurgen Seidel
    • 1
  • David Thomasson
    • 1
  • Peter Jahrling
    • 1
    • 2
  1. 1.Integrated Research Facility, National Institutes of Allergy and Infectious Diseases, National Institutes of HealthFrederickUSA
  2. 2.Emerging Viral Pathogens SectionNational Institute of Allergy and Infectious Diseases, National Institutes of HealthBethesdaUSA

Personalised recommendations